Regorafenib in the treatment of recurrent glioblastoma: a clinical case
- Authors: Moskvina E.A.1, Naskhletashvili D.R1, Bekyashev A.K.1, Roshchina K.E1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: Vol 29, No 11/12 (2022)
- Pages: 141-146
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321118
- DOI: https://doi.org/10.18565/pharmateca.2022.11-12.141-146
- ID: 321118
Cite item
Open Access
Access granted
Abstract
Glioblastoma is a recurrent malignant brain tumor. The life expectancy of such patients remains extremely low. Most patients have a tumor recurrence during the first year after its diagnosis, despite ongoing complex therapy. Glioblastoma is a highly vascularized tumor, and the efficacy of regorafenib as an inhibitor of multiple protein kinases, including kinases involved in tumor angiogenesis, was studied in the phase II randomized, multicentre, open-label trial REGOMA. The article presents a brief review of the study and a clinical case of prescribing regorafenib in combination with bevacizumab in the 3rd line of therapy for a patient with glioblastoma without MGMT gene methylation and IDH1 and IDH2 mutations in the tumor. The time to progression was 5 months.
Full Text
About the authors
Ekaterina A. Moskvina
N.N. Blokhin National Medical Research Center of Oncology
Email: k.moskvina@mail.ru
Cand. Sci. (Med.), Researcher at the Department of Neurosurgery (Oncology) Moscow, Russia
D. R Naskhletashvili
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
A. Kh Bekyashev
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
K. E Roshchina
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
References
- Kruchko C, Ostrom Q.T, Gittleman H., Barnholtz-Sloan J.S. The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro Oncol. 2018;20:295-98. Doi: 10.1093/ neuonc/noy006.
- Stupp R, Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96. Doi: 10.1056/ NEJMoa043330.
- Batchelor T.T., Mulholland P., Neyns B., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31:3212-18. Doi: 10.1200/ JCO.2012.47.2464.
- Wick W., Puduvalli V.K., Chamberlain M.C., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168-74. doi: 10.1200/JCO.2009.23.2595.
- Taal W., Oosterkamp H.M., Walenkamp A.M., et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943-53. doi: 10.1016/S1470-2045(14)70314-6.
- Wick W., Gorlia T., Bendszus M., et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954-63. Doi: 10.1056/ NEJMoa17073 58.
- Wong M.L., Prawira A., Kaye A.H., Hovens C.M. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009;16:1119-30. doi: 10.1016/j.jocn.2009.02.009.
- Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40. Doi: 10.1200/ JCO.2 008.19.8721.
- Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-29. Doi: 10.1200/ JCO.2007.12.2440.
- Lombardi G., Pambuku A., Bellu L., et al. Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2017;111:94-102. doi: 10.1016/j.critrevonc.2017.01.018.
- Gilbert M.R., Dignam J.J., Armstrong T.S., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699-708. Doi: 10.1056/ NEJMoa13085 73.
- Chinot O.L., Wick W., Mason W., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709-22. Doi: 10.1056/ NEJMoa1308345.
- Michaelsen S.R., Staberg M., Pedersen H., et al. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro Oncol. 2018;20:1462-74. doi: 10.1093/neuonc/noy103.
- Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
- Bruix J., Qin S., Merle P., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;389:56-66. doi: 10.1016/S0140-6736(16)32 453-9.
- Demetri G.D., Reichardt P., Kang Y.K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2013;381:295-302. doi: 10.1016/S0140-6736(12)61857-1.
- Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 2013;381:303-12. doi: 10.1016/S0140-6736(12)61900-X.
- Wilhelm S.M., Dumas J., Adnane L., et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.Int J Cancer. 2011;129:245-55. doi: 10.1002/ijc.25864.
- Hamed H.A., Tavallai S., Grant S., Poklepovic A., Dent P. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. J Cell Physiol. 2015;230:131-139. doi: 10.1002/jcp.24689.
- Lombardi G., De Salvo G.L., Brandes A.A., et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20;1:110-19. doi: 10.1016/S1470-2045(18)30675-2.
- Weller M., Tabatabai G., Kastner B. et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21:2057-64. doi: 10.1158/1078-0432. CCR-14-2737.
- Kebir S., Rauschenbach L., Radbruch A., et al. Regorafenib in patients with recurrent high-grade astrocytoma. J Cancer Res Clin Oncol. 2019;145:1037-42. doi: 10.1007/s00432-019-02868-5.
- Tzaridis T., Gepfner-Tuma I., Hirsch S., et al. Regorafenib in advanced high-grade glioma: A retrospective bicentric analysis. Neuro-Oncology. 2019;21:954-55. doi: 10.1093/neuonc/ noz071.
- Lombardi G., Caccese M., Padovan M., et al. Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study. Cancers (Basel). 2021;13(18):4731. Doi: 10.3390/ cancers13184731.
Supplementary files
